Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Our licensed therapists are just waiting to cover new topics you care about
Not available in clinics yet
Novel insights into GIP receptor targeting treatment reveal that both GIP receptor antagonists and agonists, when combined with glucagon like peptide 1 (GLP-1) receptor activation, are associated with improved glycemic control and weight loss
The most significant results came from the in vivo animal studies
Conclusions In this large real-world cohort of patients with type 2 diabetes and pre-existing aortic aneurysm, GLP-1RA therapy was associated with significantly lower risks of aortic rupture/dissection, hypertensive crisis, and all-cause mortality compared with DPP-4i therapy
